India’s Jubilant To Expand In U.S. Generics Market
This article was originally published in PharmAsia News
Executive Summary
Jubilant Organosys of India plans to market 10 generic drugs a year in the U.S. and Europe as it expands its presence in the two markets. European regulators have cleared the firm's plant in Roorkee intended for the expansion; U.S. FDA approval is expected within the next six months. So far, none of Jubilant's filings for market approval is a first-to-file application that would give it 180 days of generic exclusivity. Jubilant currently markets nine generics in the U.S., producing them in a U.S. plant, and has five in the approval stage. (Click here for more